Disease Brain News Today

BioArctic: Results from lecanemab confirmatory phase 3 Clarity AD study to be presented at 15th Clinical Trials on Alzheimer's Disease (CTAD) conference - read this article along with other careers information, tips and advice on BioSpace

/PRNewswire/ -- BioArctic ABs (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will present the efficacy, safety and biomarker results from the Phase 3...

In a new study of Alzheimer's disease, researchers at UC San Francisco have discovered that a relatively unstudied form of the tau protein associated with neurodegeneration may be a means for better diagnosis and treatment of the disease.

Fragmented tau that accumulates in neurons in those with Alzheimer's disease may be a new target for drugs to treat the neurodegenerative disease.

Extreme drowsiness during the day is a common sign of Alzheimer's disease, but what causes it? We now have an answer thanks to a recent study. Even after

Medical center took a close look at immune cells the protect the brain against disease they discovered that these cells only function if intestinal bacteria can produce certain substances that they need. the mother wasnt easy usually visa called micro cells are very active in the brain they have small appendages which monitor the nerve cells of the central nervous system if bacterial metabolites short chain fatty acids disappear then visa immune cells are hampered they wither away like plants in...